# Beyond the Pseudogene: p17/PERMIT as a Mitochondrial Trafficking Protein Linking Aging and Neurodegeneration

## TL;DR

A protein called p17/PERMIT, once thought to be a pseudogene, is shown to help mitochondria function and may play a role in aging and neurodegeneration.

## Contribution

p17/PERMIT is reclassified as a functional mitochondrial trafficking protein from a previously annotated pseudogene.

## Key findings

- p17/PERMIT facilitates ER-to-mitochondria translocation of CerS1, enabling C18-ceramide synthesis and mitophagy.
- Loss of p17/PERMIT impairs mitochondrial quality control and accelerates neurodegeneration in aging and injury models.
- The study provides a validation pipeline for identifying functional proteins in the noncoding genome.

## Abstract

The misclassification of functional genomic loci as pseudogenes has long obscured critical regulators of cellular homeostasis, particularly in aging‐related pathways. One such locus, originally annotated as RPL29P31, encodes a 17‐kDa protein now redefined as PERMIT (Protein that Mediates ER–Mitochondria Trafficking). Through rigorous experimental validation—including antibody development, gene editing, lipidomics, and translational models—p17/PERMIT has emerged as a previously unrecognized mitochondrial trafficking chaperone. Under aging or injury‐induced stress, p17 mediates the ER‐to‐mitochondria translocation of Ceramide Synthase 1 (CerS1), facilitating localized C18‐ceramide synthesis and autophagosome recruitment to initiate mitophagy. Loss of p17 impairs mitochondrial quality control, accelerating neurodegeneration, and sensorimotor decline in both injury and aging models. This Perspective highlights p17 as a paradigm‐shifting discovery at the intersection of lipid signaling, mitochondrial biology, and genome reannotation, and calls for a broader reassessment of the “noncoding” genome in aging research. We summarize a rigorous multi‐platform validation pipeline—including gene editing, antibody generation, lipidomics, proteomics, and functional rescue assays—that reclassified p17 as a bona fide mitochondrial trafficking protein. Positioned at the intersection of lipid metabolism, organelle dynamics, and genome reannotation, p17 exemplifies a growing class of overlooked proteins emerging from loci historically labeled as pseudogenes, urging a systematic reevaluation of the “noncoding” genome in aging research.

This Perspective highlights the experimental validation of p17/PERMIT, a mitochondrial trafficking protein encoded by a locus previously annotated as a pseudogene. The work outlines a generalizable framework for uncovering functional proteins hidden in the noncoding genome, with implications for mitochondrial quality control and aging‐related neurodegeneration.